Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K39/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/206677ANTI-VISTA ANTIBODY AND APPLICATION THEREOF
WO 06.10.2022
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/CN2022/083390 Applicant BIO-THERA SOLUTIONS, LTD. Inventor HUANG, Wenlong
The present invention provides an anti-VISTA antibody or an antigen-binding segment, and an application thereof. The antibody or the antigen-binding segment of the present invention can specifically bind to VISTA, and block the interaction between VISTA and a ligand thereof. The antibody or the antigen-binding segment of the present invention can facilitate the removal of tumor cells by an immune system, and can also be used for the diagnosis and prognosis of tumors or cancers.
2.WO/2022/206752DRUG COMBINATION OF TOLL-LIKE RECEPTOR 7 AGONIST AND ANTI-PD-L1 ANTIBODY
WO 06.10.2022
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/CN2022/083661 Applicant CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. Inventor XU, Zhongnan
Provided is a drug combination of a Toll-like receptor 7 agonist and an anti-PD-L1 antibody. In particular, provided are a drug combination of a compound, which is represented by formula I and which acts as a TLR7 agonist, and an anti-PD-L1 antibody, and a medical use thereof.
3.WO/2022/206767USE OF GPR34 INHIBITOR IN PREPARATION OF DRUG FOR TREATING DEMYELINATION-RELATED DISEASES
WO 06.10.2022
Int.Class A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
Appl.No PCT/CN2022/083739 Applicant UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA Inventor ZHOU, Rongbin
Provided is the use of a substance that reduces the expression level of the GPR34 gene and/or a function inhibitor and/or an antagonist of the GPR34 protein in the preparation of a drug for treating demyelination-related diseases. The demyelination-related diseases are selected from multiple sclerosis, cerebral ischemic stroke, transverse myelitis, Parkinson's disease, Alzheimer's disease, spinal cord injury disease, traumatic brain injury, amyotrophic lateral sclerosis, frontotemporal dementia, schizophrenia, epilepsy, etc.
4.WO/2022/206857ANTIBODY CAPABLE OF SPECIFICALLY BINDING TO HUMAN ENDOTHELIN RECEPTOR, AND USE THEREOF IN TREATMENT OF DIABETIC NEPHROPATHY AND CHRONIC NEPHROPATHY
WO 06.10.2022
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/CN2022/084164 Applicant GMAX BIOPHARM LLC Inventor ZHANG, Cheng
Provided herein are an ETAR antibody and a pharmaceutical composition thereof, also provided herein is a method for treating, preventing or ameliorating one or more symptoms of diabetic nephropathy and one or more symptoms of chronic nephropathy.
5.WO/2022/206962RECOMBINANT ONCOLYTIC VIRUS AND MEDICAL USE THEREOF
WO 06.10.2022
Int.Class C12N 7/01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
01Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
Appl.No PCT/CN2022/084842 Applicant ASCENTAWITS PHARMACEUTICALS, LTD. Inventor DUAN, Jianxin
Provided is a recombinant oncolytic virus obtained by means of integrating a coding sequence capable of expressing the RNA or DNA of a targeted enzyme in tumor cells into the genome of an oncolytic virus, wherein the recombinant oncolytic virus is combined with an antitumor prodrug activated by the targeted enzyme to improve the antitumor effect of the oncolytic virus. Also provided is a recombinant oncolytic virus, characterized in that the recombinant oncolytic virus is a selective replication-type oncolytic virus, a coding sequence capable of expressing the RNA or DNA of a targeted enzyme in tumor cells is integrated in the genome of the recombinant oncolytic virus, and the targeted enzyme is an enzyme capable of activating an antitumor prodrug. Further provided is a pharmaceutical composition, which comprises the recombinant oncolytic virus and a targeted enzyme-activated antitumor prodrug.
6.WO/2022/207652METHODS OF TREATMENT USING PROTEIN BINDERS TO IRHOM2 EPITOPES
WO 06.10.2022
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/EP2022/058301 Applicant SCIRHOM GMBH Inventor SCHNEIDER, Matthias
The present disclosure relates to a method for inhibiting or reducing TACE/ADAM17 activity in a human or animal subject. The method comprises administering to the human or animal subject an effective amount for reducing or inhibiting TACE/ADAM 17 activity of a protein binder which, when bound to human iRhom2, binds at least within a region of Loop 1 thereof, or of a nucleic acid that encodes for at least one chain of a protein binder which, when bound to human iRhom2, binds at least within a region of Loop 1 thereof.
7.WO/2022/207727ANTIBODY AND USE THEREOF FOR THE TREATMENT OF CANCER
WO 06.10.2022
Int.Class C07K 16/24
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
24against cytokines, lymphokines or interferons
Appl.No PCT/EP2022/058454 Applicant CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS Inventor CASAL ÁLVAREZ, José Ignacio
The present invention relates to a monoclonal antibody that specifically binds to an epitope comprising the amino acid sequence SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 or SEQ ID NO: 5 and capable of blocking the binding of IL-13 to IL13Ra2 or inhibiting the IL13/IL13R2 signaling, as well as the antiserum, the kit and the pharmaceutical composition comprising said monoclonal antibody. The invention also relates to the use of the antibody, the antiserum and the pharmaceutical composition in the treatment of cancer, specifically, cancer metastasis.
8.WO/2022/207922IMMUNOGENIC COMPOSITION CONTAINING AN ANTIGEN AND AN ADJUVANT COMPRISING AL-MOFs
WO 06.10.2022
Int.Class A61K 39/08
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
02Bacterial antigens
08Clostridium, e.g. Clostridium tetani
Appl.No PCT/EP2022/058789 Applicant UNIVERSITE DE VERSAILLES-SAINT-QUENTIN-EN-YVELINES Inventor JACQUES HENRI MAX, Cohen
The present invention relates to an immunogenic composition containing at least one antigen and at least one adjuvant comprising at least one Metal-Organic Framework comprising an inorganic part based on aluminum and an organic part based on polydentate ligand chosen from fumarate, muconate, mesaconate, oxalate, oxaloacetate, succinate, malate, citrate, aconitate, isophthalate, substituted isophthalate, 2,5-thiophenedicarboxylate, 2,5-furandicarboxylate, trimesate, trimellitate and pyromellitate, said antigen being immobilized at least within said Metal-Organic Framework.
9.WO/2022/208567ANTIBODY-DERIVED SINGLE CHAIN FRAGMENT VARIABLE (SCFV) AND ITS USE FOR THE IDENTIFICATION OF THE EXTRACELLULAR PORTION OF CD79B FOR THERAPEUTIC AND DIAGNOSTIC PURPOSES
WO 06.10.2022
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/IT2022/050079 Applicant FALINI, Brunangelo Inventor FALINI, Brunangelo
The present invention relates to the field of antibodies and their application for diagnostic and immunotherapeutic purposes in onco-hematology. In particular, the present invention relates to the development of a monoclonal antibody, of the G type immunoglobulin group, capable to recognize and bind the extracellular portion of the human CD79B protein (Figure 1) and to its medical use in the immunotherapy field of lymphomas expressing CD79B through the single chain fragment variable (scFv) region of the antibody.
10.WO/2022/210742PEPTIDE OF NOROVIRUS ORIGIN, POLYNUCLEOTIDE, ANTIBODY, COMPOSITION, METHOD FOR IDENTIFYING NEUTRALIZING EPITOPE FOR NOROVIRUS
WO 06.10.2022
Int.Class C12N 15/40
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
Appl.No PCT/JP2022/015581 Applicant DENKA COMPANY LIMITED Inventor FUKUSHIMA, Naoshi
The present invention provides a peptide that can be used to induce protective immunity to a norovirus that has a GII genotype. Provided is a peptide that includes a portion of the amino acid sequence of the P domain of the VP1 protein of a norovirus that has any genogroup II (GII) genotype (except genotype 4).